Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, is pleased to announce that it has received peer-approved publication of its “virtual human and rat” system, known as Cloe PK®. The details of extensive validation results for Cloe PK® showing how the technology can estimate blood levels of new drugs without the use of animals, have been accepted for publication by “Drug Metabolism and Disposition”, a prestigious peer-reviewed journal encompassing work in this scientific area.
In addition, Cyprotex has been awarded a grant by The Department of Trade & Industry (DTI) to extend the group’s predictive technologies used in the invention of new drugs. This news follows a recent announcement that Cyprotex is to form its own research group, Cyprotex Research Ltd, which will be aimed at eradicating drug liabilities from the very earliest stages of drug discovery. The research group, which will be headed by Dr David Leahy, Cyprotex’s Founder and Chief Technical Officer, will form academic and industrial collaborations to develop computational capabilities, to facilitate R&D productivity improvements throughout the industry. New tools and capabilities developed via the research group will be commercialised and offered to Cyprotex’s pharmaceutical and biotechnology partners.
Commenting on the news, Dr Leahy said “Peer-reviewed acceptance of our work on Cloe PK® is an important landmark and a clear endorsement of Cyprotex’s scientific excellence. This technology, along with the new methodologies which we will develop as a result of the DTI grant, will help us to make the next step in our drive towards understanding and eradicating the problems associated with how new drugs are processed by the body.”
For further information:
Dr Karen Jones, Business Development
Tel: +44 1625 505 100
Pope Woodhead & Associates Ltd
Tel: +44 (0) 1480 300300